The implementation of screening for prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 3, 2010, Pages 218-227

  Van Leeuwen, P J ^a   Van Vugt, H A ^a   Bangma, C H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

DRE; Early detection; Mass screening; Mortality; PSA

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; HUMAN; LUNG CANCER; OCCULT BLOOD TEST; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

DIGITAL RECTAL EXAMINATION; HEALTH PLAN IMPLEMENTATION; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77955708637     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.14     Document Type: Review

References (84)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421-429.
3. SEER. SEER Cancer Statistics Review 1975-200 http://seercancer gov/csr/1975-2006/results-merged/topic-lifetime-riskpdf; 2006.
4. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445-452.
5. Dixon H, Scully M, Wakefield M, Murphy M. The prostate cancer screening debate: public reaction to medical controversy in the media. Public Underst Sci 2009; 18: 115-128.
6. Habbema JD, van Oortmarssen GJ, van der Maas PJ. Mass screening for cancer: the interpretation of findings and the prediction of effects on morbidity and mortality. Clin Lab Med 1982; 2: 627-638.
7. Pienta KJ. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology 2009; 73 (5 Suppl): S11-S20.
8. Wilson JM, Jungner YG. (Principles and practice of mass screening for disease). Bol Oficina Sanit Panam 1968; 65: 281-393.
9. Luciano S, Berman N. Population cancer screening in Canada: strategic and priorities. Canadian Strategy for Cancer Control 2000; 21: 1-11.
10. Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep 2004; 53 (RR-1): 1-29.
11. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-319.
12. Davidson PGJ. Should mass screening for prostate cancer be introduced at the national level?. WHO Regional Office for Europe: Copenhagen. Available at http://wwweurowhoint/ Document/E82958pdf; 2004.
13. Union E. Council recommendation on cancer screening. Official J Eur Union 2003; L 327/34.
14. Committee UNS. Second report of the UK National Screening Committee. Available at www.nscnhsuk 2004; 2004.
15. Regelgeving W-e. Wet op het bevolkingsonderzoek. http://wettenoverheidnl; 2009.
16. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
17. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62 (5 Suppl 1): 27-33.
18. Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92 (Suppl 2): 1-13. (Pubitemid 38091131)
19. Sindhwani P, Wilson CM. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6: 307-312.
20. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int 2008; 101: 5-10.
21. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70. (Pubitemid 41002840)
22. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al. Prevalence of prostate cancer among men with a prostate-specific antigen level p4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
23. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853-1858.
24. Schroder FH, Carter HB,Wolters T, van den Bergh RC, Gosselaar C, Bangma CH et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468-477.
25. Postma R, Schroder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89-97. (Pubitemid 46803013)
26. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y et al. Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-473; discussion 473-564
27. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21 (6 Suppl): 251S-272S.
28. Loeb S, Catalona WJ. What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? Nat Clin Pract Urol 2009; 6: 68-69.
29. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863-869.
30. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-1823.
31. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/ml or less. Urology 2001; 58: 994-998.
32. Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/ml. Urology 2005; 66: 803-807.
33. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433-438. (Pubitemid 40528606)
34. Borden Jr LS, Wright JL, Kim J, Latchamsetty K, Porter CR. An abnormal digital rectal examination is an independent predictor of Gleason X7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int 2007; 99: 559-563.
35. Ghavamian R, Blute ML, Bergstralh EJ, Slezak J, Zincke H. Comparison of clinically nonpalpable prostate-specific antigendetected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 1999; 54: 105-110.
36. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007; 70: 1117-1120.
37. Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, Cruijsen- Koeter I, van der Kwast TH et al. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 2006; 66: 625-631.
38. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound. Curr Opin Urol 2000; 10: 111-116.
39. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166: 856-860.
40. Villers A, Malavaud B, Rebillard X, Bataille V, Iborra F. ERSPC: features and preliminary results of France. BJU Int 2003; 92 (Suppl 2): 27-29.
41. Berenguer A, Lujan M, Paez A, Santonja C, Pascual T. The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92 (Suppl 2): 33-38. (Pubitemid 38091137)
42. Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003; 92 (Suppl 2): 39-43. (Pubitemid 38091138)
43. Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Hafeli A et al. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 2003; 92 (Suppl 2): 44-47.
44. Finne P, Stenman UH, Maattanen L, Makinen T, Tammela TL, Martikainen P et al. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003; 92 (Suppl 2): 22-26.
45. Ciatto S, Gervasi G, Frullini P, Zendron P, Zappa M. Specific features of the Italian section of the ERSPC. BJU Int 2003; 92 (Suppl 2): 30-32.
46. Roobol MJ, Schroder FH. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 2003; 92 (Suppl 2): 117-122.
47. Andriole GL, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN et al. Mortality results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med 2009; 360: 1310-1319.
48. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
49. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 2005; 174: 121-125.
50. Grubb III RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: 1524-1530.
51. van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schroder FH. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 2006; 68: 615-620.
52. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009; 360: 1320-1328.
53. Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J et al. The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC). Int J Cancer 2010; 126: 2387-2393.
54. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M et al. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584-591.
55. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH et al. Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. Eur J Cancer 2010; 46: 377-383.
56. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003; 105: 394-399.
57. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 2003; 92 (Suppl 2): 97-100. (Pubitemid 38091150)
58. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol 2008; 180: 2409-2413; discussion 2414.
59. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-1261.
60. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006; issue no. (4).
61. Poplack SP, Tosteson AN, Grove MR, Wells WA, Carney PA. Mammography in 53,803 women from the New Hampshire mammography network. Radiology 2000; 217: 832-840.
62. Vejborg I, Olsen AH, Jensen MB, Rank F, Tange UB, Lynge E. Early outcome of mammography screening in Copenhagen 1991-1999. J Med Screen 2002; 9: 115-119.
63. Wang H, Karesen R, Hervik A, Thoresen SO. Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 2001; 12: 39-45.
64. Institute NC. Inventory of colorectal cancer screening activities in ICSN countries, June 2006. Available at http://appliedre searchcancergov/icsn/ colorectal/screeninghtml; 2006.
65. Hewitson P, Glasziou P, Irwig L, Towler B,Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; issue no. (1).
66. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549.
67. Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S et al. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev 2004; 13: 19-26.
68. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104. (Pubitemid 34779153)
69. Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. Cochrane Database Syst Rev 2004; issue no. (1).
70. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004; 126: 114-121.
71. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247-1249.
72. Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005; 116: 617-623.
73. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004; 8: iii 1-78.
74. Cancer research UK. Prostate cancer. UK Incidence Statistics. Cancer Research: UK, 2009.
75. Integraal Kankercentrum Rotterdam. IKCnet. http://wwwikc netnl/IKR/indexphp; 2009.
76. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH. et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-878.
77. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79-85.
78. Roobol MJ, Schroder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N et al. A framework for the identification of men at increased risk for prostate cancer. J Urol 2009; 182: 2112-2120.
79. Crawford ED, Andriole GL, Marberger M, Rittmaster RS. Reduction in the risk of prostate cancer: future directions after the prostate cancer prevention trial. Urology 2010; 75: 502-509.
80. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
81. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
82. Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman Jr CA. Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 2008; 71: 854-857.
83. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007; 177: 1749-1752.
84. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128-1133.